This review summarizes and considers possible strategies to further enhance the clinical efficacy of peptide receptor radionuclide therapy in gastroenteropancreatic and lung neuroendocrine tumors.  Cives M & Strosberg J. Curr Oncol Rep 2017; 19: 9. doi:10.1007/s11912-017-0567-8

This chapter discusses the genetic and epigenetic alterations and molecular pathway dysregulations that are proposed to be involved in the pathogenesis of esophageal neuroendocrine tumors. Seydafkan S & Coppola D. In:  Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances . Edited by Nasir A & Coppola D. Springer New York, 2016. doi:10.1007/978-1-4939-3426-3_11

Here, changes in the 8th edition of the AJCC staging system for neuroendocrine tumors of the pancreas, jejunum/ileum, and appendix are highlighted. Nakakura EK. Ann Surg Oncol . 2017. doi:10.1245/s10434-017-6026-9

This review summarizes recent advances in the therapy of advanced gastroenteropancreatic-neuroendocrine tumors, delineating possible approaches for the management of this heterogeneous group of malignancies. Cives M & Strosberg J.  Curr Treat Options in Oncol 2017; 18: 14. doi:10.1007/s11864-017-0461-5

Wolin et al. outline how lanreotide depot provides potential advantages to both patients and healthcare providers in the treatment of gastroenteropancreatic neuroendocrine tumors. Wolin EM et al. J Gastrointest Canc 2016; 47: 366–374. doi:10.1007/s12029-016-9866-9

The review discusses the imaging of neuroendocrine tumors, which, with the increased availability of somatostatin receptor-targeted positron emission tomography tracers, has refocused on targeted imaging. Hope TA et al. Clin Transl Imaging 2017; 5: 63–69. doi:10.1007/s40336-016-0193-8

The incidence and prevalence of neuroendocrine tumors has increased about four-fold in the last 30 years due to diagnostic improvements. The authors provide a summary of the available epidemiological data. Kilickap S & Hayran KM. In: Neuroendocrine Tumours . Edited by Yalcin S & Öberg K. Springer Berlin Heidelberg, 2015. doi:10.1007/978-3-662-45215-8_3

Vinik et al. examined the health-related quality of life (HRQoL) of sunitinib-treated patients with pancreatic neuroendocrine tumors and found that survival increased without adversely affecting HRQoL. Vinik A et al. Targ Oncol 2016; 11: 815–824. doi:10.1007/s11523-016-0462-5

General self-efficacy, social support, and cancer-related stress are key factors in coping with a neuroendocrine tumor diagnosis. This study found that improving these factors may improve health-related quality of life. Haugland T et al. Health Qual Life Outcomes 2016; 14: 11. doi:10.1186/s12955-016-0413-y

In this study, the authors find peptide receptor radionuclide therapy to be effective in the treatment of pancreatic neuroendocrine tumors whilst also improving the quality of life of patients. Marinova M, et al. Eur J Nucl Med Mol Imaging 2017. doi:10.1007/s00259-017-3816-z

A propensity score-matched analysis was  here utilized to assess the impact of primary tumor location on prognosis of patients undergoing curative intent liver resection for neuroendocrine liver metastasis. Spolverato G  et al. J Gastrointest Surg . 2017. doi: 10.1007/s11605-017-3491-1

The authors investigated whether the use of a web-based system, involving self-screening, patient education, and self-referral to professional healthcare, is feasible in patients with neuroendocrine tumors. Bouma G et al. Support Care Cancer 2017; 25: 2075–2083. doi:10.1007/s00520-017-3598-7